Organogenesis Holdings Ownership
| ORGO Stock | USD 4.98 0.16 3.32% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 132.2 M | Current Value 126.3 M | Avarage Shares Outstanding 92.1 M | Quarterly Volatility 49.1 M |
Organogenesis | Build AI portfolio with Organogenesis Stock |
Organogenesis Stock Ownership Analysis
About 46.0% of the company outstanding shares are owned by corporate insiders. The book value of Organogenesis Holdings was now reported as 1.92. The company recorded a loss per share of 0.16. Organogenesis Holdings had not issued any dividends in recent years. Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 950 people. To find out more about Organogenesis Holdings contact Gary Sr at 781 575 0775 or learn more at https://organogenesis.com.Besides selling stocks to institutional investors, Organogenesis Holdings also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Organogenesis Holdings' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Organogenesis Holdings' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Organogenesis Holdings Quarterly Liabilities And Stockholders Equity |
|
Organogenesis Holdings Insider Trades History
About 46.0% of Organogenesis Holdings are currently held by insiders. Unlike Organogenesis Holdings' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Organogenesis Holdings' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Organogenesis Holdings' insider trades
Organogenesis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Organogenesis Holdings is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Organogenesis Holdings backward and forwards among themselves. Organogenesis Holdings' institutional investor refers to the entity that pools money to purchase Organogenesis Holdings' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 1.1 M | Renaissance Technologies Corp | 2025-03-31 | 1 M | Aqr Capital Management Llc | 2025-03-31 | 893.8 K | D. E. Shaw & Co Lp | 2025-03-31 | 884.3 K | Charles Schwab Investment Management Inc | 2025-03-31 | 835 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 667.5 K | Lazard Asset Management Llc | 2025-03-31 | 649.4 K | Northern Trust Corp | 2025-03-31 | 593.4 K | Sg Americas Securities, Llc | 2025-03-31 | 525.4 K | Soleus Capital Management, L.p. | 2025-03-31 | 12.5 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 12.1 M |
Organogenesis Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organogenesis Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organogenesis Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Organogenesis Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Organogenesis Holdings Outstanding Bonds
Organogenesis Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Organogenesis Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Organogenesis bonds can be classified according to their maturity, which is the date when Organogenesis Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US68622TAB70 Corp BondUS68622TAB70 | View | |
| US68622TAA97 Corp BondUS68622TAA97 | View |
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Organogenesis Stock
| 0.64 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Organogenesis Stock
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.16) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.